The Canada Diabetes Market is Segmented Into Drugs (by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by Sub-Segment (Basal or Long-Acting, Bolus or Fast-Acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors)) and Devices (Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-Monitoring Blood and Continuous Glucose Monitoring)). The Market Provides the Value (in USD) and Volume (in Units) for the Above-Mentioned Segments.

The Canada Diabetes Care Devices Market is segmented into management devices (insulin pumps, insulin syringes, disposable insulin pens, insulin cartridges in reusable pens, and insulin jet injectors) and monitoring devices (self-monitoring blood glucose (glucometer devices, test strips, and lancets) and continuous glucose monitoring (sensors and receivers (receivers and transmitters))). The report offers the value (in USD million) and volume (in units million) for the above segments.

The report on North America Diabetes Care Devices & Drugs covers a summarized study of several factors supporting market growth, such as market size, market type, major regions, and end-user applications. The report enables customers to recognize key drivers that influence and govern the market.

The diabetes care device market size is projected to grow from USD 39.82 billion in 2025 to USD 99.81 billion by 2035, representing a CAGR of 9.62% during the forecast period till 2035

In 2023, the diabetes care devices market generated over 26 billion U.S. dollars in global revenues. The market was forecast to increase year-on-year and reach over 52.3 billion U.S. dollars by 2029.

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and health

The Diabetes Care Devices Market is segmented by Management Devices (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors), Monitoring Devices (Self-monitoring Blood Glucose and Continuous Glucose Monitoring), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The Industry Report Offers Values (USD Billion) for the Above Segments.

Access the summary of the Diabetes Care Devices market report, featuring key insights, executive summary, market size, CAGR, growth rate, and future outlook.

Global Diabetes Care Devices Drugs market size 2025 was XX Million. Diabetes Care Devices Drugs Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

The global diabetes care devices market size was valued at USD 34.19 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 62.65 Billion by 2033, exhibiting a CAGR of 6.61% from 2025-2033. North America currently dominates the market, holding a market share of over 38.6% in 2024. The rising incidences of diabetes, rapid technological advancements, imposition of favorable government initiatives, increasing disposable incomes, integration of big data and analytics, and escalating geriatric population are some of the major factors propelling the market.

IMARC Group provides an analysis of the key trends in each segment of the global diabetes care devices market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on type, distribution channel and end user.

The pet diabetes care devices market is capturing a valuation of US$ 2.3 billion in 2023 and is expected to reach US$ 4.3 billion by 2033. The market is registering a CAGR of 6.2% during the forecast period.

Scope of Report

The size of the Mexico Diabetes Drugs and Devices market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of > 0.00% during the forecast period.Controlling diabetes with drugs and devices: a chronic condition that raises blood sugar above normal levels. Drugs include medications that normalize the production of insulin by the pancreas, those that increase the body's sensitivity to insulin, and those that lower blood sugar itself. This includes insulin injections; oral drugs, such as metformin; newer drugs, such as GLP-1 receptor agonists; and SGLT-2 inhibitors. Diabetes products not only measure the blood glucose levels but also control the administration of insulin and continuous glucose monitoring. The products start right from a basic blood glucose meter to advanced insulin pumps and continuous glucose monitoring systems that have developed quite significantly in the last couple of years. Leading drivers of the Mexican diabetes drugs and devices market are increasing prevalence of diabetes, primarily type 2 diabetes. Urbanization, sedentary lifestyle, and other unhealthy dietary habits are other driving forces causing an uptrend of diabetic patients in the country.The market is being driven by the increasing need for innovative, effective diabetes treatments; besides drug therapies, advanced devices are also key drivers. Additionally, involvement of government initiatives related to healthcare access and affordability has a positive effect on the market. Diabetes drugs and devices in Mexico are going to experience tremendous growth because of the growing demand for holistic diabetes management solutions in the changing Mexican health care setting. Recent developments include: October 2022: Becton, Dickinson, and Company and Biocorp signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology. It is a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes., March 2022: Oramed announced ORMD-0801 (a new molecule) is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule with the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets.. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period.

The size of the Iran Diabetes Drugs and Devices market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of > 4.32% during the forecast period.Diabetes drugs and devices are the essential tools in the management and treatment of a chronic disorder that is usually characterized by high blood sugar levels. Drugs for diabetes either modify insulin release, enhance the action of insulin, or directly decrease blood glucose. The available drugs are insulin, oral antidiabetic drugs, and newer classes of drugs including GLP-1 receptor agonists and SGLT-2 inhibitors.The diabetes devices help patients monitor and track their blood glucose levels. Examples of the various types of devices include blood glucose meters, continuous glucose monitoring systems, insulin pumps, and pen injectors. Information relayed by the devices to the patients in terms of real-time measurement of blood sugar determines diet, exercise, and medication decisions.Iran's diabetes drugs and devices market is significant as the pattern of increasing prevalence of diabetes among the population is clearly visible. Aging, lifestyle, and genetic factors are promoting an increase in disease cases. The authorities in Iran have implemented various measures to reduce the ever-increasing burden of diabetes - access to healthcare, low cost of medication, and public awareness campaigns.However, economy sanctions and currency fluctuations make it difficult for drugs and diabetes equipment to reach without a hike in price. However, still, the market is working on growing, not because of drug but, mainly for generics and locally produced devices.With advancement in the Iranian healthcare system, diabetic solutions that are innovative and at affordable prices will be in demand more. Recent developments include: August 2022: Tirzepatide, A weight-loss drug, is now available in UAE to treat Type 2 diabetes. Mounjaro, or Tirzepatide, is a US Food and Drug Administration-approved injectable prescription medication used to improve blood sugar, or glucose, through weight loss., February 2022: Abbott said it has tied up with various health-tech firms like BeatO Sugar.fit, PharmEasy, GOQii, 1MG, and Zyla for diabetes care. The company said it has also joined hands with Health, HealthifyMe, and Fitterfly under the initiative.. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period.

The revenue in the 'Diabetes Care Devices' segment of the medical technology market in Africa was forecast to continuously increase between 2024 and 2029 by in total 810.9 million U.S. dollars (+79.85 percent). After the twelfth consecutive increasing year, the revenue is estimated to reach 1.8 billion U.S. dollars and therefore a new peak in 2029. Notably, the revenue of the 'Diabetes Care Devices' segment of the medical technology market was continuously increasing over the past years.Find further information concerning the revenue in the 'General & Plastic Surgery Devices' segment of the medical technology market in Indonesia and the revenue change in the 'Medical Devices' segment of the medical technology market in Indonesia. The Statista Market Insights cover a broad range of additional markets.

This statistic depicts the market share of the global top diabetes care devices manufacturers in 2011. In that year, Medtronic from the United States had a 7.5 percent share in the total global market for diabetes care devices.

Top diabetes care devices manufacturers

Diabetes is one of the leading causes of death in the United States. In 2010, 20.8 people per 100,000 of the U.S. population died due to diabetes. In the United States, 239 billion U.S. dollars was expended in 2013 to treat diabetes. However, in China, a country with one of the largest number of diabetics in the world, only 38 billion U.S. dollars was spent on diabetes health care. The diabetes care market is expected to grow to almost 16 billion U.S. dollars in the United States by 2017.

In 2011, F.Hoffman-La Roche Ltd and LifeScan, Inc. together are considered a large part of the top diabetes care device manufacturers in the world at 15.2 percent and 14.2 percent of the global market share, respectively. Lifescan is part of the Johnson & Johnson Company and has developed glucose monitoring devices such as OneTouch Ultra for home and hospital use. About 61 percent of global diabetes care devices can be listed under the glucose monitoring device category and 24 percent under insulin delivery devices. Insulin pump therapy has vastly improved since the 1970s, with alarms for malfunction and wireless connection to meters and computers. This type of device is a widely used product for diabetics around the world.

Stay updated with the latest Diabetes Care Devices Market News. Get insights on recent mergers, acquisitions, and key industry developments.

Explore the Pet Diabetes Care Global Market Report 2025 Market trends! Covers key players, growth rate 9.7% CAGR, market size $3.49 Billion, and forecasts to 2033. Get insights now!

The China Diabetes Drugs and Devices Market report is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood and continuous glucose monitoring)). The report offers the value (in USD) and volume (in units) for the above segments.

[213+ Pages Report] The global Diabetes Management Market size is expected to grow from USD 18.23 billion in 2022 to USD 36.02 billion by 2030, at a CAGR of 8.87% from 2023-2030

Asia-Pacific Diabetes Care Devices Market size was valued at USD 8.2 Billion in 2023 and is anticipated to reach USD 15.7 Billion by 2031, growing at a CAGR of 8.5% from 2024 to 2031.

Key Market Drivers:
Rising Incidence of Diabetes: The Asia-Pacific region has a high prevalence of diabetes, with more than 60% of the world’s diabetic population residing in this area. For instance, India and China alone account for approximately 90 million and 62 million diabetics, respectively, highlighting the urgent need for effective diabetes management solutions.

Growing Geriatric Population: The aging population in Asia-Pacific countries is contributing to an increase in diabetes cases. The World Health Organization projects that the number of older adults (aged 60 and above) will reach 1.3 billion by 2050, leading to a higher demand for diabetes care devices tailored for elderly patients.